FNY
First Trust Mid Cap Growth AlphaDEX Fund
First Trust Mid Cap Growth AlphaDEX Fund seeks investment results that correspond to the Defined Mid Cap Growth Index.
US
EQUITY
Rules-Based
MANAGEMENT STYLE
$ 581.6 M
ASSETS UNDER MGMT
70 bp
EXPENSES
Fund Basics
| Inception date | Apr 19, 2011 |
| Regulation | Open-Ended Fund |
| Fund Website | link... |
| Distributions | Quarterly |
| Currency | USD |
| Holdings Transparency | Full |
| Derivatives-based | No |
| Options available | Yes |
| Currency hedged | No |
| Fund of funds | No |
Top 10 Holdings
Complete list +
| ETSY, INC. | 0.9 % |
| PACS GROUP INC | 0.9 % |
| GUARDANT HEALTH, INC. | 0.8 % |
| AMNEAL PHARMACEUTICALS, INC. CLASS A | 0.8 % |
| BRIGHTSPRING HEALTH SERVICES, INC. | 0.8 % |
| TG THERAPEUTICS INC | 0.8 % |
| FRONTDOOR, INC. | 0.8 % |
| VICTORIA'S SECRET & COMPANY | 0.8 % |
| COMPASS INC CLASS A | 0.8 % |
| LANTHEUS HOLDINGS INC | 0.8 % |
Constituent Breakdown
| Number of holdings | 226 |
| Herfindahl-Hirschman Index | 53 |
| Wgt avg mkt cap (mns) | $9,225 |
| Large cap (>$10bn) | 41.0% |
| Mid cap ($2-10bn) | 57.3% |
| Small cap (<$2bn) | 0.0% |
| Developed mkts. | 98.3% |
| Emerging mkts. | 0.0% |
Sector Breakdown
Country Exposure
 |
UNITED STATES | 97.5 % |
Historical Performance
Standardized Performance (as of 06/30/2026)
| YTD | 1 YR | 2 YR | 3 YR | 5 YR | 10 YR | 20 YR | Incep. | |
|---|---|---|---|---|---|---|---|---|
| Price Returns | 21.6% | 34.5% | 22.7% | 19.6% | 8.0% | 14.0% | -- | 11.7% |
| Dividend Yield | 0.0% | 0.0% | 0.2% | 0.2% | 0.2% | 0.3% | -- | 0.3% |
| Total Returns | 21.6% | 34.5% | 23.0% | 19.8% | 8.2% | 14.2% | -- | 12.1% | Ann. Volatility | 22.5% | 20.7% | 22.5% | 21.0% | 22.4% | 22.4% | -- | 21.0% |
Market Correlations
| versus... | Beta | R-squared |
| S&P 500 | 1.38 | 69% |
| MSCI EAFE | 0.97 | 53% |
| MSCI Emg Mkts | 0.66 | 53% |
Liquidity Measures
| Avg. volume (000) | 32 |
| ADV traded (mns) | $3 |
| Turnover | 0.6% |
| Avg. Bid/Ask (% of price) | 0.20% |
Technical Indicators
| 30d moving avg. (EMA) | $105.32 |
| Relative strength (RSI) | 49 |
| MACD/Signal | -0.31/0.33 |
| Bollinger Bands (Upper/Lower) | $111.02/$102.47 |
| Short interest (% of AUM) | 1.3% |
Distributions
Top Ten Comparable ETFs only shown here. For an extended list become an Individual or Professional subscriber. Start your FREE trial
Comparable ETFs Based on Overlap
| Ticker | Fund Name | Overlap vs. FNY |
Expenses vs. FNY |
ALTAR Score™ vs. FNY |
|---|---|---|---|---|
| FNX | First Trust Mid Cap Core AlphaDEX Fund | 37.3% | -10 bp | +4.3% |
| ISCG | iShares Morningstar Small-Cap Growth ETF | 36.3% | -64 bp | +0.4% |
| VBK | Vanguard Small-Cap Growth ETF | 32.0% | -63 bp | -1.0% |
| MDYG | State Street SPDR S&P 400 Mid Cap Growth ETF | 31.6% | -55 bp | +2.0% |
| IJK | iShares S&P Mid-Cap 400 Growth ETF | 31.4% | -53 bp | +1.9% |
| IVOG | Vanguard S&P Mid-Cap 400 Growth ETF | 30.7% | -60 bp | +2.0% |
| FAD | First Trust Multi Cap Growth AlphaDEX Fund | 29.6% | -6 bp | -0.6% |
| BKMC | BNY Mellon US Mid Cap Core Equity ETF | 26.9% | -66 bp | +17.6% |
| VIOG | Vanguard S&P Small-Cap 600 Growth ETF | 25.3% | -60 bp | +1.3% |
| JHSC | John Hancock Multifactor Small Cap ETF | 25.2% | -28 bp | +3.5% |
Risk and Returns: FNY vs. Comps (1 YR)
Notes: Top 10 overlapping ETFs. Funds with insufficient history not shown. Some funds may overlap. Hover over data point for ticker symbol.
Content on this tab for Individual & Professional subscribers only. Start your FREE trial
Results & Estimates (USD)
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | ||
|---|---|---|---|---|---|---|---|---|---|
| Sales per share | -- | -- | -- | -- | -- | -- | -- | ||
| change (%) | -- | -- | -- | -- | -- | -- | -- | ||
| Earnings per share | -- | -- | -- | -- | -- | -- | -- | ||
| change (%) | -- | -- | -- | -- | -- | -- | -- | ||
| Dividends per share | -- | -- | -- | -- | -- | -- | -- | ||
| change (%) | -- | -- | -- | -- | -- | -- | -- | ||
| Book value per share | -- | -- | -- | -- | -- | -- | -- | ||
| change (%) | -- | -- | -- | -- | -- | -- | -- |
Return on Equity
Net Margins
Content on this tab for Individual & Professional subscribers only. Start your FREE trial
Valuation Metrics
| Fwd Est | 2025 | 2026 | 2027 | |
| Price-to-sales | --x | --x | --x | --x |
| Price-to-earnings | --x | --x | --x | --x |
| Price-to-cash flow | --x | --x | --x | --x |
| Price-to-growth | --x | --x | --x | --x |
| Price-to-book value | --x | --x | --x | --x |
| Yield | --% | --% | --x | --% |
Based on closing prices from 7/21/2026
Peer Group Comparison
Sample data. Subscribe for access.
Historical Valuation Trends Sample data. Subscribe for access.
Notes: Based on adjusted historical results for current fund constituents. May differ from results achieved by past fund constituents. Max P/E of 100x.
Some content on this tab for Individual & Professional subscribers only. Start your FREE trial
ETF Research Center Rating
3.0%
ALTAR SCORE™
12nd
PERCENTILE
AVOID
ETFRC RATING
There are 1,398 funds in the US Equity category with an average
ALTAR Score™ of 5.4% and a standard deviation
of 2.1%. FNY's ALTAR Score™ is approximately -1.2 standard
deviations above the category average. This places FNY in the 12nd percentile
among funds in the category.
Sell-Side Consensus
$116.24
PRICE TARGET
+12.9%
UPSIDE